Definium Therapeutics (DFTX) stock is in focus after the company reported first quarter 2026 results, including a net loss of US$77.1 million, compared with US$23.35 million in the same period a year earlier.

The earnings update comes after a strong run in the stock, with a 90 day share price return of 37.28% and a year to date share price return of 70.09%. Meanwhile, the 1 year total shareholder return of 259.13% and 3 year total shareholder return of more than 6x highlight how much sentiment has already shifted.

If this kind of swing in risk appetite around Definium has your attention, it can be useful to widen your watchlist and look at 35 healthcare AI stocks

With the stock up sharply while losses widen, the key question now is whether Definium is still trading at a discount to its potential or if the market is already pricing in years of future growth.

Most Popular Narrative: 34.1% Undervalued

At the last close of $23.20 against a narrative fair value of $35.23, Definium is framed as materially discounted, with that gap hinging on ambitious long term assumptions.

Approaching three pivotal Phase III readouts for DT120 ODT in GAD and MDD in 2026 positions the company to potentially transition from a pure R&D story toward a commercial stage profile, which could materially affect future revenue visibility and earnings power if outcomes support regulatory filings.

Want to see what sits behind that potential shift from zero revenue to a full commercial profile? The narrative leans on aggressive revenue build, margin expansion and a premium future earnings multiple tied to blockbuster level uptake. Curious how those moving parts combine into a single fair value line for Definium?

Result: Fair Value of $35.23 (UNDERVALUED)

However, this hinges on DT120 ODT clearing Phase III and regulatory hurdles, while ongoing losses and expected share issuance keep funding and dilution firmly in play.

Next Steps

With both risks and rewards in view, are you comfortable with where sentiment sits today, or do you need more evidence before acting? Take a closer look at the balance of potential upside and downside in the 1 key reward and 4 important warning signs

Looking for more investment ideas?

If Definium is already on your radar, do not stop there. Use the Simply Wall Street Screener to uncover other stocks that might suit your style.

• Spot potential value opportunities early by scanning 51 high quality undervalued stocks before others catch on.
• Strengthen your watchlist with companies that have robust finances by checking the solid balance sheet and fundamentals stocks screener (44 results).
• Hunt for lesser known opportunities with strong fundamentals by filtering through the screener containing 23 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.